Clinical Trial Update: Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM) [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating the effect of sacubitril/valsartan (an ARNI) on ventricular arrhythmias in patients with heart failure and reduced ejection fraction …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Entresto (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Heart Failure | Phase 4 | Status: TERMINATED | Results posted: 2024-10-17